Bioethics News

Ten years since the discovery of iPS cells. The current state of their clinical application

  Rev Clin Esp. 2017 Jan – Feb;217(1):30-34. doi: 10.1016/j.rce.2016.08.003. Epub 2016 Oct 5.
Justo Aznar Ph.D. MD
Julio Tudela Pharm Ph.D.
Institute of Life Science – Bioethics Observatory
Catholic University of Valencia – Spai

iPS cells current clinical applications

Abstract

On the 10-year anniversary of the discovery of induced pluripotent stem – cells iPS cells, we review the main results from their various fields of application, the obstacles encountered during experimentation and the potential applications in clinical practice. The efficacy of induced pluripotent cells in clinical experimentation can be equated to that of human embryonic stem cells (see HERE); however, unlike stem cells, induced pluripotent cells do not involve the severe ethical difficulties entailed by the need to destroy human embryos to obtain them (see HERE). The finding of these cells, which was in its day a true scientific milestone worthy of a Nobel Prize in Medicine, is currently enveloped by light and shadow: high hopes for regenerative medicine versus the, as of yet, poorly controlled risks of unpredictable reactions, both in the processes of dedifferentiation and subsequent differentiation to the cell strains employed for therapeutic or experimentation goals (see more HERE).

KEYWORDS:

Cell reprogramming; Embryonic stem cells; Regenerative medicine; iPS cells

*Discovery of iPS cells, see HERE

*See HERE our article, Stem cell treatments with embryonic and iPS cells. Their usefulness (12-09-2016).

Photo: NATURE

 

La entrada Ten years since the discovery of iPS cells.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.